Recombinant Cynomolgus NKG2A&CD94 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01586P-100UG

Cynomolgus NKG2A&CD94 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Cynomolgus NKG2A&CD94 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01586P-100UG
Collections: All products, High-quality recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Cynomolgus NKG2A&CD94 Protein is expressed from HEK293 with His tag and Flag tag at the C-Terminus.It contains Pro94-Leu233(NKG2A)&Lys32-Ile179(CD94). |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | Q68VD2(NKG2A)&Q68VD4(CD94) |
Target Symbol | NKG2A&CD94 |
Synonyms | CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94 |
Species | Cynomolgus |
Expression System | HEK293 |
Tag | C-His, C-Flag |
Expression Range | Pro94-Leu233(NKG2A) & Lys32-Ile179(CD94) |
Mol. Weight | The protein has a predicted MW of 17.01 kDa(NKG2A)&18.27 kDa(CD94). Due to glycosylation, the protein migrates to 25-35 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Cynomolgus NKG2A&CD94, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Anti-NKG2A Antibody, hFc Tag with the EC50 of 8.7g/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies. |